Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicaid Payment Model For Sickle Cell Gene Therapy May Have Limited Impact Until 2026

Executive Summary

As further details emerge, questions continue about whether the CMMI model could delay access to Lyfgenia and Casgevy; states will be added on ‘rolling basis.’ A new administration could change or cancel the model, but a CMS official predicts that is unlikely.

You may also be interested in...

Sickle Cell Gene Therapy Makers Would Pay For Fertility Services In Medicaid Payment Model

The manufacturer requirement, which invokes CMMI’s safe harbor authority, could help overcome some barriers to access that the companies are facing in Medicaid outside of the demonstration. 

Sickle Cell Gene Therapy In Medicaid: CMMI Model As ‘Bandwidth Extender’ For Less Resourced States

Outcomes-based contract that federal government will negotiate with manufacturers on behalf of Medicaid programs might not be appealing to large states. Bluebird and Vertex can apply to the demonstration project this spring and negotiations would follow between May and November.

Bluebird’s Fast Lyfgenia Launch Was A Year And A Half In The Making; Medicaid Talks Continuing

When Zynteglo was approved for beta-thalassemia, bluebird said launch would lay groundwork for sickle cell gene therapy Lyfgenia. The strategy is paying off so far with a fast ramp-up. Outcomes-based contracts for Lyfgenia give payers rebate based on hospitalizations over a three-year period.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts